Press Releases

- GW intends to advance oncology research and development efforts - LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its

- Epidiolex ® NDA submission and launch preparation on track - - New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline -  - Conference call today at 8:30 a.m. EST - LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the

LONDON, Jan. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 February, 2017 its

- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 - - NDA submission and launch preparation on track - - Conference call today at 8:00 a.m. EST - LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical

- Posters Presented at American Epilepsy Society Annual Meeting - - New data includes key secondary efficacy endpoints - LONDON , Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and

-  Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites  - -  GW will also unveil its new U.S. operating name, Greenwich Biosciences, Inc.   - LONDON, Dec.

LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December,

LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin

- Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo -  - Today's data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 - - Data reinforce the potential of Epidiolex to be an important new medicine for patients

LONDON, Sept. 07, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin